Firefly Neuroscience, Inc. (AIFF) Aandelenanalyse

Bedrijfsoverzicht

Firefly Neuroscience, Inc. is a medical technology and artificial intelligence enterprise dedicated to delivering neuroscientific solutions designed to enhance brain health outcomes for patients suffering from mental illnesses and neurological disorders. The company operates within the Technology sector, specifically the Software - Application industry, positioning it as a provider of specialized diagnostic and analytical tools for the healthcare market. Its current market capitalization stands at $23.57 million, while its trailing twelve-month revenue totals $1.14 million, and the available employee count is listed as N/A. These valuation and revenue figures indicate that the company remains a small-cap entity with limited scale, suggesting it is likely in an early growth phase where revenue expansion takes precedence over profitability or significant workforce deployment.

Financiële gezondheid

The company reported revenue of $1.14 million for the trailing twelve months, yet this generated a net income of -$24,531,000 and an EBITDA of -$8,464,000. The substantial gap between the positive revenue figure and the deeply negative net income reveals a cost structure where operating expenses significantly outpace earnings, a common characteristic for firms in the software development stage. Free cash flow stands at -$6,578,250, which indicates that the company is burning cash to fund its operations and research initiatives rather than generating surplus liquidity for distribution. Despite these outflows, the balance sheet holds $2.75 million in cash and maintains zero debt, providing a buffer to sustain operations without the pressure of mandatory interest payments. The analysis of margins shows a gross margin of 56.5%, reflecting efficient production or service delivery relative to direct costs, while the operating margin of -583.0% and profit margin of 0.0% highlight severe overhead burdens relative to sales. The company's current ratio is 1.43, indicating that it possesses sufficient current assets to cover its short-term liabilities, though the liquidity position is strained by continuous cash burn. Return on Equity is -547.6% and Return on Assets is -70.9%, metrics that reveal management is currently destroying value per unit of capital employed rather than generating returns.

Waarderingsbeoordeling

The P/E Ratio (TTM) and Forward P/E are both listed as N/A due to the lack of positive earnings, which implies that traditional earnings-based valuation models are not applicable at this stage of the company's financial lifecycle. The price-to-book ratio is 2.74, indicating that the market values the company at a premium of 174% over its tangible book value, a multiple often seen in technology firms where intangible assets and future growth potential are priced in. Alternative valuation metrics show a price-to-sales ratio of 20.64 and an EV/EBITDA of -2.30, suggesting the market is willing to pay a high multiple for revenue given the expectation of future profitability once the current losses narrow. Regarding price metrics, the 52-week high is $4.51 and the 52-week low is $0.62, meaning the stock trades within a volatile range with a spread of approximately $3.89 between its peak and trough. The Beta is listed as N/A, preventing a direct comparison of the stock's volatility relative to the broader market, though the wide 52-week range suggests significant price instability typical of small-cap biotech or software stocks.

Growth & Income

Revenue growth year-over-year is 677.4%, while earnings growth year-over-year is N/A due to the continued negative net income position. Since earnings are negative, they cannot grow faster or slower than revenue in a traditional sense, but the massive revenue expansion suggests the business model is scaling rapidly despite high burn rates. The company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which implies that all available cash is being reinvested into the company's growth operations and research and development efforts rather than distributed to shareholders. Overall, the growth and income profile characterizes Firefly Neuroscience as a high-risk, high-revenue-growth entity that prioritizes market expansion and product development over generating current cash returns or providing income to investors.